Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes

Inclusion Criteria:

- Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months

- Treatment with basal insulin regimen (insulin detemir, insulin glargine or neutral
protamine Hagedorn [NPH] insulin) once daily (OD), for at least 3 months

- Ongoing treatment with: metformin with or without other oral antidiabetic drugs
(OADs) for at least 3 months prior to randomisation

- HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis

- BMI maximum 40.0 kg/m^2

Exclusion Criteria:

- Treatment with insulin regimens other than a basal insulin regimen (insulin detemir
or insulin glargine or NPH insulin) OD within 3 months prior to Visit 1

- Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists within 3 months
prior to visit 1

- Current rosiglitazone users

- Cardiovascular disease, within the last 6 months prior to visit 1, defined as:
stroke; decompensated heart failure New York Heart Association (NYHA) class III or
IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass
graft or angioplasty

- Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least
180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)

- Impaired liver function, defined as alanine aminotransferase (ALAT) at least 2.5
times upper limit of normal (one retest analysed at the central laboratory within a
week of receipt of the result is permitted with the result of the last sample being
conclusive)

- Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
contraceptive measures according to local requirements

- Cancer and medical history of cancer hereof (except basal cell skin cancer or
squamous cell skin cancer)